Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis
- 29 February 1996
- journal article
- clinical trial
- Published by Elsevier BV in Bone
- Vol. 18 (2), 141-150
- https://doi.org/10.1016/8756-3282(95)00436-x
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Bone density at various sites for prediction of hip fracturesThe Lancet, 1993
- Prevention and treatment of osteoporosis: A review of current modalitiesBone, 1992
- Effects of 4-amino-1-hydroxybutylidene bisphosphonate on bone biomechanics in ratsJournal of Bone and Mineral Research, 1992
- Comparison of the therapeutic potencies of two bisphosphonatesBone, 1992
- The bisphosphonate, alendronate, prevents bone loss in ovariectomized baboonsJournal of Bone and Mineral Research, 1992
- Bone mineral density in the proximal femur and hip fracture type in the elderlyJournal of Bone and Mineral Research, 1992
- The bisphosphonate alendronate (MK-217) inhibits bone loss due to ovariectomy in ratsJournal of Bone and Mineral Research, 1991
- PamidronateDrugs, 1991
- Effect of Fluoride Treatment on the Fracture Rate in Postmenopausal Women with OsteoporosisNew England Journal of Medicine, 1990
- RISK-BENEFIT RATIO OF SODIUM FLUORIDE TREATMENT IN PRIMARY VERTEBRAL OSTEOPOROSISThe Lancet, 1988